

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition comprising a substantially purified composition including an adhesive and a polypeptide comprising amino acid sequence

LKKTET SEQ ID NO:1 or a conservative variant thereof, amino acid sequence
KLKKTET SEQ ID NO:2, LKKTETQ SEQ ID NO:3, Thymosin β4 (Tβ4), an N-terminal
variant of Tβ4, a C-terminal variant of Tβ4, an isoform of Tβ4, a splice-variant of Tβ4,
oxidized Tβ4, lymphoid Tβ4, pegylated Tβ4, Tβ4^{ala}, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13,
Tβ14, Tβ15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, adsevertin,
propomyosin, fincillin, depactin, DnaseI, villin, fragmin, severin, capping protein, β-
actinin or acumentin.

2. (Original) The composition of claim 1 wherein said adhesive is capable of adhering to tissue of a living subject.

3. (Currently Amended) The composition of claim 2-1 wherein said adhesive is biodegradable.

4. (Original) The composition of claim 1 wherein said adhesive is fibrin, fibrinogen, fibrin glue, collagen, a fragment thereof, or a mixture thereof.

5. (Original) The composition of claim 4 wherein said adhesive and said polypeptide are covalently bound together.

6. (Original) The composition of claim 5 wherein said adhesive and said polypeptide are covalently bound by factor XIIIa.

7. (Original) The composition of claim 6 wherein said adhesive is a fragment of fibrin or fibrinogen.

8. (Previously Presented) The composition of claim 1 wherein said polypeptide comprises amino acid sequence KLKKTET SEQ ID NO:2 or LKKTETQ SEQ ID NO:3, Thymosin β 4 (T β 4), an N-terminal variant of T β 4, a C-terminal variant of T β 4, an isoform of T β 4, a splice-variant of T β 4, oxidized T β 4, T β 4 sulfoxide, lymphoid T β 4 or pegylated T β 4.

9. (Original) The composition of claim 1 wherein said polypeptide is recombinant or synthetic.

10. (Original) The composition of claim 1 wherein said polypeptide is an antibody.

11. (Original) The composition of claim 10 wherein said antibody is polyclonal or monoclonal.

12. (Original) The composition of claim 4 wherein the concentration of said polypeptide is within a range of about 0.01-1 mole said polypeptide per mole of said adhesive.

13. (Original) The composition of claim 12 wherein said range is about 0.1-0.5 mole said polypeptide per mole of said adhesive.

14. (Original) The composition of claim 13 wherein said range is about 0.2-0.4 mole said polypeptide per mole of said adhesive.

15. (Original) The method of delivering a polypeptide to a site, comprising introducing the composition of claim 1 to said site.

16. (Previously Presented) The method of claim 15 wherein said composition is applied to said site by spraying.

17. (Original) The method of claim 16 wherein said site is a wound.

18. (Original) The method of claim 15 wherein said adhesive is capable of adhering to tissue of a living subject.

19. (Currently Amended) The method of claim 18 15 wherein said adhesive is biodegradable.

20. (Original) The method of claim 15 wherein said adhesive is fibrin, fibrinogen, fibrin glue, collagen, a fragment thereof or a mixture thereof.

21. (Original) The method of claim 20 wherein said adhesive is covalently bound to said polypeptide.

22. (Original) The method of claim 21 wherein said adhesive is covalently bound to said polypeptide by factor XIIIa.

23. (Original) The method of claim 22 wherein said adhesive is a fragment of fibrin or fibrinogen.

24. (Previously Presented) The method of claim 15 polypeptide comprises amino acid sequence KLKKTET SEQ ID NO:2 or LKKTETQ SEQ ID NO:3, Thymosin

β 4 (T β 4), an N-terminal variant of T β 4, a C-terminal variant of T β 4, an isoform of T β 4, a splice-variant of T β 4, oxidized T β 4, T β 4 sulfoxide, lymphoid T β 4 or pegylated T β 4.

25. (Original) The method of claim 15 wherein said polypeptide is recombinant or synthetic.

26. (Original) The method of claim 15 wherein said polypeptide is an antibody.

27. (Original) The method of claim 26 wherein said antibody is polyclonal or monoclonal.

28. (Original) The method of claim 20 wherein said polypeptide is a concentration that is within a range of about 0.1-1 mole said polypeptide per mole of said adhesive.

29. (Original) The method of claim 28 wherein said range is about 0.1-0.5 mole said polypeptide per mole of said adhesive.

30. (Original) The method of claim 29 wherein said range is about 0.2-0.4 mole said polypeptide per mole of said adhesive.

31. (New) The composition of claim 1 wherein said polypeptide is TB4.

32. (New) The method of claim 15 wherein said polypeptide is TB4.